Lethal prostate cancer (PCa) is more likely to develop in men with a prostate-specific antigen (PSA) level above the median in midlife, according to a new study.
Using data from the Physicians’ Health Study, Mark A. Preston, MD, MPH, of Brigham and Women’s Hospital in Boston, and colleagues performed a case-control analysis of 234 mostly white men diagnosed with PCa and 711 controls aged 40 to 59 at baseline.
